ATE295730T1 - Prävention und behandlung von auf ischämie- reperfusion und auf endotoxine zurückzuführende schäden unter verwendung von adenosin- und purin- rezeptor-antagonisten - Google Patents

Prävention und behandlung von auf ischämie- reperfusion und auf endotoxine zurückzuführende schäden unter verwendung von adenosin- und purin- rezeptor-antagonisten

Info

Publication number
ATE295730T1
ATE295730T1 AT95914863T AT95914863T ATE295730T1 AT E295730 T1 ATE295730 T1 AT E295730T1 AT 95914863 T AT95914863 T AT 95914863T AT 95914863 T AT95914863 T AT 95914863T AT E295730 T1 ATE295730 T1 AT E295730T1
Authority
AT
Austria
Prior art keywords
ischemia
adenosine
reperfusion
prevention
treatment
Prior art date
Application number
AT95914863T
Other languages
English (en)
Inventor
Constance F Neely
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE295730T1 publication Critical patent/ATE295730T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT95914863T 1994-03-30 1995-03-24 Prävention und behandlung von auf ischämie- reperfusion und auf endotoxine zurückzuführende schäden unter verwendung von adenosin- und purin- rezeptor-antagonisten ATE295730T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/219,946 US5504090A (en) 1994-03-30 1994-03-30 Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
PCT/US1995/003702 WO1995026728A1 (en) 1994-03-30 1995-03-24 Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists

Publications (1)

Publication Number Publication Date
ATE295730T1 true ATE295730T1 (de) 2005-06-15

Family

ID=22821384

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914863T ATE295730T1 (de) 1994-03-30 1995-03-24 Prävention und behandlung von auf ischämie- reperfusion und auf endotoxine zurückzuführende schäden unter verwendung von adenosin- und purin- rezeptor-antagonisten

Country Status (7)

Country Link
US (1) US5504090A (de)
EP (1) EP0755254B1 (de)
AT (1) ATE295730T1 (de)
CA (1) CA2186915C (de)
DE (1) DE69534215T2 (de)
ES (1) ES2239319T3 (de)
WO (1) WO1995026728A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017953A (en) * 1993-12-28 2000-01-25 Allergan Sales, Inc. Thromboxane ligands
US5733916A (en) * 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US5874420A (en) * 1995-12-26 1999-02-23 Allegheny University Of The Health Sciences Process for regulating vagal tone
AU741713B2 (en) * 1997-03-25 2001-12-06 Duska Scientific Co. Modulation of human mast cell activation
AU740770B2 (en) * 1997-06-18 2001-11-15 Aderis Pharmaceuticals, Inc. Compositions and methods for preventing restenosis following revascularization procedures
WO1999034803A1 (en) * 1998-01-09 1999-07-15 The Trustees Of The University Of Pennsylvania Compositions and methods for use in ischemia-reperfusion and endotoxin-related tissue injury
US6117445A (en) * 1998-01-28 2000-09-12 Link Technology Inc. Methods for the prevention and treatment of fibrosis and sclerosis
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
IT1303815B1 (it) * 1998-12-02 2001-02-23 Consiglio Nazionale Ricerche Impiego di selettivi composti modulatori dei recettori purinici p2 perla prevenzione dei danni e della mortalita' causata da ischemia
ATE306489T1 (de) 1999-03-08 2005-10-15 Medicure Inc Pyridoxal-analoge zur behandlung von störungen ausgelöst durch einen vitamin b6 mangel
CA2376029A1 (en) * 1999-07-13 2001-01-18 Medicure Inc. Use of pyridoxin derivatives for the treatment of diabetes and related complications
JP2003507418A (ja) * 1999-08-24 2003-02-25 メディキュア インターナショナル インコーポレイテッド 心血管疾患とその関連疾患の治療
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
WO2001064692A1 (en) 2000-02-29 2001-09-07 Medicure International Inc. Cardioprotective phosphonates and malonates
US6586414B2 (en) 2000-03-28 2003-07-01 Medicure International Inc. Treatment of cerebrovascular disease
AU2001272263B2 (en) 2000-07-07 2005-12-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
EP1305023A4 (de) * 2000-08-01 2005-02-23 Univ Virginia Verwendung selektiver agonisten, antagonisten und allosterischer verstärker des adenosin-a1-rezeptors zur beeinflussung der angiogenese
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
US20040121988A1 (en) * 2001-03-28 2004-06-24 Medicure International Inc. Treatment of cerebrovascular disease
US6599283B1 (en) * 2001-05-04 2003-07-29 Cv Therapeutics, Inc. Method of preventing reperfusion injury
EP1385523B1 (de) * 2001-05-08 2008-08-06 Blanchette Rockefeller Neurosciences Institute Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
EP1390740A4 (de) * 2001-05-24 2007-04-04 Endacea Inc Verfahren und formulierungen zur erhöhung der affinität von a 1? -adenosinrezeptorliganden für den a 1? -adenosinrezeptor
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
EP1465634B1 (de) 2001-12-12 2014-10-22 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Verfahren zur verwendung adenosinrezeptorinhibitoren zur verstärkung der immunantwort und entzündung
US20040121406A1 (en) * 2002-05-23 2004-06-24 Wilson Constance Neely Methods and formulations for increasing the affinity of a1 adenosine receptor ligands for the a1 adenosine receptor
AU2003237460A1 (en) * 2002-06-06 2003-12-22 Endacea, Inc. Combination treatments for purinoceptor-related disorders
EA200500782A1 (ru) * 2002-11-07 2005-10-27 Юниверсити Оф Питтсбург Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Лечение геморрагического шока
EP1601649A4 (de) * 2003-02-19 2009-03-04 Endacea Inc A1-adenosinrezeptorantagonisten
US20040186077A1 (en) * 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
CA2528385C (en) * 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists
US20060019929A1 (en) * 2004-07-07 2006-01-26 Albert Friesen Combination therapies employing platelet aggregation drugs
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
CA2585165A1 (en) * 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
WO2007059631A1 (en) * 2005-11-28 2007-05-31 Medicure International Inc. Selected dosage for the treatment of cardiovascular and related pathologies
US20070208042A1 (en) 2006-03-03 2007-09-06 Sherwood Services Ag Method of using vasoconstrictive agents during energy-based tissue therapy
US10092591B2 (en) * 2014-02-27 2018-10-09 University Of Alaska Fairbanks Methods and compositions for the treatment of ischemic injury to tissue using therapeutic hypothermia
CA3045508A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods for modulation of car-t cells
CA3045355A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
MX2019006438A (es) 2016-12-05 2019-11-28 Juno Therapeutics Inc Produccion de celulas modificadas para terapia de celulas adoptivas.
AU2018275894A1 (en) 2017-06-02 2019-12-12 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
EP3644721A1 (de) 2017-06-29 2020-05-06 Juno Therapeutics, Inc. Mausmodell zur auswertung von toxizitäten im zusammenhang mit immunotherapien
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
US20210132042A1 (en) 2017-11-01 2021-05-06 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
US11623961B2 (en) 2017-11-01 2023-04-11 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
CN111989106A (zh) 2017-12-01 2020-11-24 朱诺治疗学股份有限公司 基因工程化细胞的给药和调节方法
MA51184A (fr) 2017-12-15 2020-10-21 Juno Therapeutics Inc Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
CN113646335A (zh) 2018-11-01 2021-11-12 朱诺治疗学股份有限公司 使用对b细胞成熟抗原具有特异性的嵌合抗原受体的治疗的方法
US20210393689A1 (en) 2018-11-01 2021-12-23 Juno Therapeutics, Inc. Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
EP3880238A1 (de) 2018-11-16 2021-09-22 Juno Therapeutics, Inc. Verfahren zur dosierung von manipulierten t-zellen zur behandlung von b-zell-malignitäten
JP2022513685A (ja) 2018-11-30 2022-02-09 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法を用いた処置のための方法
PE20212198A1 (es) 2019-01-29 2021-11-16 Juno Therapeutics Inc Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1)
KR20230009386A (ko) 2020-04-10 2023-01-17 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
US20240041929A1 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7810947L (sv) * 1978-10-20 1980-04-21 Draco Ab 3-alkylxanthines
US4769377A (en) * 1983-02-18 1988-09-06 The Johns Hopkins University Adenosine receptor antagonists
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US4772607A (en) * 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US4904472A (en) * 1987-04-10 1990-02-27 The University Of Virginia Alumni Patent Foundation Use of adenosine antagonists in the treatment of bradyarrhythmias and mechanical dysfunction associated with cardiopulmonary resuscitation
US4829054A (en) * 1987-04-13 1989-05-09 Miles Laboratories, Inc. Method of decreasing lung damage in a host following the onset of gram negative septicemia/endotoxemia
US5066655A (en) * 1987-04-24 1991-11-19 Whitby Research, Inc. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
US4980379A (en) * 1988-06-30 1990-12-25 The University Of Virginia Use of adenosine antagonists in the treatment of bradyarrhythmias and hemodynamic depression associated with cardiopulmonary resucitation and/or cardiovascular collapse
US5032593A (en) * 1988-07-01 1991-07-16 Marion Merrell Dow Inc. Method of treating bronchoconstriction with 1,3-unsymmetrical straight chain alkyl-substituted 8-phenylxanthines
US5298508A (en) * 1988-07-19 1994-03-29 The United States Of America As Represented By The Department Of Health And Human Services Irreversible inhibitors of adenosine receptors
US5175290A (en) * 1988-09-16 1992-12-29 Marion Merrell Dow Inc. 8-(oxo-substituted cycloalkyl)xanthines
JP2843634B2 (ja) * 1989-03-06 1999-01-06 協和醗酵工業株式会社 キサンチン誘導体
US5256650A (en) * 1989-03-29 1993-10-26 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
US5200176A (en) * 1989-10-06 1993-04-06 Genentech, Inc. Method for protection of ischemic tissues using tumor nerosis factor
US5162361A (en) * 1990-04-10 1992-11-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Method of treating diseases associated with elevated levels of interleukin 1
IT1240843B (it) * 1990-05-24 1993-12-17 Malesci Istituto Farmacobiologico Derivati xantinici 1-7 sostituiti ad attivita' antiasmatica, loro sali fisiologicamente accettabili, loro composizioni farmaceutiche e procedimento per la loro preparazione.
US5117830A (en) * 1990-11-08 1992-06-02 Whitby Research, Inc. Method of determining viability of tissue
GB9024738D0 (en) * 1990-11-14 1991-01-02 Erba Carlo Spa A new method of treatment of tumor necroisis factor(tnf)-related diseases
NZ240644A (en) * 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
US5236908A (en) * 1991-06-07 1993-08-17 Gensia Pharmaceuticals, Inc. Methods of treating injury to the central nervous system
US5248678A (en) * 1992-06-30 1993-09-28 Fractal Laboratories, Inc. Methods for increasing arousal and alertness and for the amelioration of comatose states
US5366977A (en) * 1992-09-29 1994-11-22 The United States Of America, As Represented By The Department Of Health And Human Services Method of treating cystic fibrosis using 8-cyclopentyl-1,3-dipropylxanthine or xanthine amino congeners
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage

Also Published As

Publication number Publication date
DE69534215T2 (de) 2005-10-13
CA2186915C (en) 2008-06-10
ES2239319T3 (es) 2005-09-16
EP0755254B1 (de) 2005-05-18
WO1995026728A1 (en) 1995-10-12
DE69534215D1 (de) 2005-06-23
US5504090A (en) 1996-04-02
EP0755254A1 (de) 1997-01-29
CA2186915A1 (en) 1995-10-12
EP0755254A4 (de) 2002-01-16

Similar Documents

Publication Publication Date Title
ATE295730T1 (de) Prävention und behandlung von auf ischämie- reperfusion und auf endotoxine zurückzuführende schäden unter verwendung von adenosin- und purin- rezeptor-antagonisten
ES2175079T3 (es) Derivados de indol utiles como inhibidores de cgmp-pde.
TR199902194T2 (xx) +p38 protein kinaz inhibit�rleri olarak ikameli azot ihtiva eden heterosikler.
KR970705556A (ko) 알레르기성 질환 치료에 유용한 신규 치환된 피페리딘(Novel substituted piperidines useful for the treatment of allergic diseases)
HK1008819A1 (en) Piperidine derivatives as neurokinin antagonists
ES2072096T3 (es) 4-fenilpiperidinas n-sustituidas antagonistas de opioides.
HUT75113A (en) 4-substituted piperidine derivatives useful as neurokinin antagonists
ES2072627T3 (es) Derivados de piridina y n-oxido de piridina de diarilmetilpiperidinas o piperazinas, composiciones y uso de las mismas.
NZ307625A (en) 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists
ATE148632T1 (de) Synergistische therapeutische zusammensetzungen und verfahren
BR0107943A (pt) Sìtios de entrada de ribossoma internos sintéticos e métodos de identificar os mesmos
ES2102154T3 (es) Inhibicion de trombina.
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
DE69133135T2 (de) Menschliche neuronale nikotin-acetylcholin-rezeptor-verbindungen und methoden ihres einsatzes
NZ308789A (en) Tetralin derivatives and medicaments
MX9805181A (es) Derivados de lactona a partir de derivados de 17.beta- carboxi, carbotio y amida androstano.
BR9607335A (pt) Compostos 1-aril-2-acrilamino-etano e seu uso como neuroquinina especialmente antogonistas de neuroquinina 1
ES2120025T3 (es) Derivados de xantina utilizados como antagonistas de receptores de adenosina a1.
TR200000291T2 (tr) Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.
TR199801988T2 (xx) Kalp yetmezli�inin endotelin antagonistleri ile tedavisi i�in y�ntem.
DE69112573T2 (de) Immunstimulierendes arzneimittel, das polare glycopeptidolipide von mycobakterium-chelonae enthält.
DE69125175D1 (de) Verwendung von angiotensin-ii-rezeptorantagonisten bei der behandlung von atheromen
DK0815126T3 (da) Bicykliske tachykinin-antagonister, fremstilling deraf og deres anvendelse i farmaceutiske præparater
DK0858807T3 (da) Anvendelse af dopaminreceptor-antagonister i palliativ tumorterapi
TR199800488T1 (xx) Diskinezi i�in 5-HT3 resept�r antagonistleri.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties